Wells Fargo’s Franklin Genomic Advancements ETF HELX Stock Holding History

Wells Fargo’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-107	Closed	-$3.22K	–	7726
2022 Q4	$3.22K	Hold	107	–	–	﹤0.01%	5890
2022 Q3	$3K	Buy	+107	New	+$3.55K	﹤0.01%	6054

Other funds holding HELX

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Wells Fargo's HELX Position: Q1 2023 in Review

Wells Fargo sold out of Franklin Genomic Advancements ETF (HELX) in Q1 2023, closing a stake of 107 shares — an estimated $3.22K sold.

Wells Fargo first reported a position in HELX in Q3 2022 and held it in 2 quarters. The position peaked at $3.22K in Q4 2022. 6 funds tracked by Wall St. Rank hold HELX as of Q1 2023.

Wells Fargo reported no remaining Franklin Genomic Advancements ETF position as of Q1 2023 after selling out during the quarter.
Wells Fargo sold 107 Franklin Genomic Advancements ETF shares in Q1 2023, an estimated $3.22K.
Wells Fargo first reported a position in Franklin Genomic Advancements ETF in Q3 2022 and held it in 2 quarters.
Wells Fargo's Franklin Genomic Advancements ETF position peaked at $3.22K in Q4 2022.
6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q1 2023.

Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.